Jennison Associates LLC Has $26.91 Million Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jennison Associates LLC decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 439,562 shares of the company’s stock after selling 38,259 shares during the period. Jennison Associates LLC’s holdings in Prestige Consumer Healthcare were worth $26,910,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Trexquant Investment LP boosted its holdings in Prestige Consumer Healthcare by 109.1% during the third quarter. Trexquant Investment LP now owns 8,340 shares of the company’s stock worth $477,000 after purchasing an additional 4,351 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in Prestige Consumer Healthcare by 91.4% during the third quarter. Qube Research & Technologies Ltd now owns 72,092 shares of the company’s stock worth $4,123,000 after purchasing an additional 34,430 shares during the last quarter. SG Americas Securities LLC bought a new stake in Prestige Consumer Healthcare during the third quarter worth $1,632,000. Connors Investor Services Inc. bought a new stake in Prestige Consumer Healthcare during the third quarter worth $1,569,000. Finally, Hsbc Holdings PLC raised its position in Prestige Consumer Healthcare by 17.1% during the third quarter. Hsbc Holdings PLC now owns 22,075 shares of the company’s stock worth $1,263,000 after acquiring an additional 3,226 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on PBH shares. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. TheStreet raised shares of Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research report on Monday, February 12th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Prestige Consumer Healthcare Stock Down 1.5 %

Shares of PBH opened at $70.13 on Thursday. The company’s 50-day moving average is $70.88 and its 200-day moving average is $64.08. Prestige Consumer Healthcare Inc. has a fifty-two week low of $55.96 and a fifty-two week high of $75.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.09 and a quick ratio of 1.92.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 8th. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $1.04 by $0.02. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The business had revenue of $282.74 million for the quarter, compared to the consensus estimate of $280.25 million. During the same period in the prior year, the company posted $1.04 earnings per share. Prestige Consumer Healthcare’s revenue was up 2.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.33 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 5,336 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the transaction, the senior vice president now directly owns 15,934 shares in the company, valued at $1,099,446. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.